Possible testosterone redundancy for 5α-dihydrotestosterone in the masculinization of mouse external genitalia.


Journal

Experimental animals
ISSN: 1881-7122
Titre abrégé: Exp Anim
Pays: Japan
ID NLM: 9604830

Informations de publication

Date de publication:
10 Nov 2022
Historique:
pubmed: 26 5 2022
medline: 15 11 2022
entrez: 25 5 2022
Statut: ppublish

Résumé

The development of embryonic external genitalia (eExG) into characteristic male structures, such as urethra and penile erectile tissues, depends on 5α-dihydrotestosterone (DHT). Although the corpus cavernosum (CC) is well known as essential for erectile function in adults, its developmental process and its dependency on DHT have been unknown. To reveal the dimorphic formation of the murine CC from the embryonic stage, we first analyzed the production of the protein vascular endothelial growth factor receptor-2 (FLK1) via its expression (hereinafter referred as "expression of FLK1") and the expression of alpha-smooth muscle actin (ACTA2) and collagen type 1 (COL1A1) in developing external genitalia. The 5-α reductase type 2 encoded by the SRD5A2 gene has been suggested to be a crucial enzyme for male sexual differentiation, as it converts testosterone (T) into DHT in the local urogenital organs. In fact, SRD5A2 mutation results in decreased synthesis of DHT, which leads to various degrees of masculinized human external genitalia (ExG). We further investigated the expression profile of SRD5A2 during the formation of the murine CC. We observed that SRD5A2 was expressed in smooth muscle of the CC. To determine the role of SRD5A2 in CC formation, we analyzed the formation of erectile tissue in the male Srd5a2 KO mice and measured the levels of androgens in the ExG by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Intriguingly, there were no obvious defects in the CCs of male Srd5a2 KO mice, possibly due to increased T levels. The current study suggests possible redundant functions of androgens in CC development.

Identifiants

pubmed: 35613877
doi: 10.1538/expanim.22-0038
pmc: PMC9671772
doi:

Substances chimiques

3-Oxo-5-alpha-Steroid 4-Dehydrogenase EC 1.3.99.5
Dihydrotestosterone 08J2K08A3Y
Membrane Proteins 0
Testosterone 3XMK78S47O
Srd5a2 protein, mouse EC 1.3.99.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

451-459

Références

J Mol Endocrinol. 2005 Oct;35(2):305-16
pubmed: 16216911
Endocrinology. 1990 Feb;126(2):1165-72
pubmed: 2298157
Gen Comp Endocrinol. 2020 May 1;290:113400
pubmed: 31981690
Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):
pubmed: 34074765
J Urol. 2000 Aug;164(2):367-70
pubmed: 10893587
J Clin Endocrinol Metab. 1996 Jan;81(1):384-9
pubmed: 8550782
Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2273-2288
pubmed: 31533473
BMC Med. 2013 Jun 24;11:152
pubmed: 23800242
J Cereb Blood Flow Metab. 2007 Nov;27(11):1841-52
pubmed: 17406656
J Androl. 2009 Jul-Aug;30(4):363-9
pubmed: 18802199
Clin Chim Acta. 2017 Jun;469:31-36
pubmed: 28288785
Endocrinology. 1984 Jun;114(6):2100-6
pubmed: 6539197
Urology. 2013 Sep;82(3):743.e9 -15
pubmed: 23876578
Endocr Rev. 2017 Jun 1;38(3):220-254
pubmed: 28472278
Prostate. 2013 Jul;73(10):1069-81
pubmed: 23423946
Mol Endocrinol. 1996 Apr;10(4):380-92
pubmed: 8721983
Reprod Health. 2016 Nov 29;13(1):140
pubmed: 27899129
Mol Endocrinol. 2009 Jun;23(6):871-80
pubmed: 19282366
J Clin Endocrinol Metab. 2011 Feb;96(2):296-307
pubmed: 21147889
Biol Reprod. 2011 Apr;84(4):631-8
pubmed: 21076079
Am J Physiol Renal Physiol. 2015 Feb 15;308(4):F358-65
pubmed: 25411386
PLoS One. 2019 Mar 6;14(3):e0212367
pubmed: 30840652
Cell. 2010 Jul 23;142(2):196-8
pubmed: 20655462
Andrology. 2017 Jan;5(1):146-152
pubmed: 27696776
J Steroid Biochem Mol Biol. 1994 Aug;50(3-4):169-74
pubmed: 8049146
Endocrinology. 2001 Nov;142(11):4652-62
pubmed: 11606430
Urol Clin North Am. 2005 Nov;32(4):379-95, v
pubmed: 16291031
Proc Soc Exp Biol Med. 1992 Nov;201(2):125-40
pubmed: 1409728
Mol Cell Endocrinol. 1992 Oct;88(1-3):15-22
pubmed: 1334007
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7194-203
pubmed: 26598695
Clin Endocrinol (Oxf). 2015 Oct;83(4):518-26
pubmed: 25899528
Mol Genet Genomic Med. 2020 Oct;8(10):e1431
pubmed: 32713132
Hormones (Athens). 2018 Jun;17(2):197-204
pubmed: 29858846
Pharmacol Rev. 2011 Dec;63(4):811-59
pubmed: 21880989
Sci Rep. 2015 Sep 08;5:13632
pubmed: 26346620
Endocrinology. 1983 Aug;113(2):569-73
pubmed: 6872940
Mol Cell Endocrinol. 1997 Oct 31;134(1):33-40
pubmed: 9406847
J Inherit Metab Dis. 1997 Mar;20(1):95-101
pubmed: 9061573
Int J Mol Sci. 2021 Oct 05;22(19):
pubmed: 34639119
Reprod Med Biol. 2021 Feb 09;20(2):199-207
pubmed: 33850453
Nature. 1991 Nov 14;354(6349):159-61
pubmed: 1944596
Sex Dev. 2021 Dec 14;:1-4
pubmed: 34903701
Andrology. 2021 Jul;9(4):1264-1274
pubmed: 33657666
Cell Tissue Res. 2002 Feb;307(2):145-53
pubmed: 11845321
Exp Anim. 2010;59(5):615-22
pubmed: 21030789
J Histochem Cytochem. 1994 May;42(5):667-75
pubmed: 8157936
J Urol. 2000 Feb;163(2):460-3
pubmed: 10647654
Congenit Anom (Kyoto). 2022 May;62(3):123-133
pubmed: 35318743
BJU Int. 1999 Jul;84(1):50-6
pubmed: 10444124
Science. 2020 Jun 5;368(6495):1132-1135
pubmed: 32499443
Endocrinology. 1989 Mar;124(3):1217-23
pubmed: 2492923

Auteurs

Yuko Ueda (Y)

Department of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, Japan.
Department of Developmental Genetics, Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.

Kentaro Suzuki (K)

Department of Developmental Genetics, Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
Faculty of Life and Environmental Sciences, University of Yamanashi, Yamanashi 400-0851, Japan.

Mizuki Kajimoto (M)

Department of Developmental Genetics, Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd. (SNBL), Kainan Intelligent Park, 16-1 Minami-Akasaka, Kainan, Wakayama 642-0017, Japan.

Kota Fujimoto (K)

Department of Developmental Genetics, Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.

Mala Mahendroo (M)

Department of Obstetrics and Gynecology, Green Center for Reproductive Biological Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9032, USA.

Masatsugu Ema (M)

Department of Stem Cells and Human Diseases Models, Research Center for Animal Life Science, Medical University of Shiga, Otsu, Shiga 520-2192, Japan.

Gen Yamada (G)

Department of Developmental Genetics, Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.

Isao Hara (I)

Department of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH